Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q2 2022 · 10-Q
Revenue—
Net Income-$2.79M-$2.79MN/M vs Q2 2021 EPS Diluted-$2.73-$2.73N/M vs Q2 2021 Operating Income-$4,706,759N/M Operating Cash Flowderived-$4,585,197N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Free Cash Flowderived-$4,639,088— ended Jun 30, 2022 · filed Aug 12, 2022 · 43 d after period end